HEPTA MEDICAL

Hepta Medical develops a minimally invasive treatment for earl-stage lung cancer patients. Our device is a microwave ablation platform, including a flexible ablation probe guided and positioned inside the tumor through the patient’s airway. The ablation probe thermally destroys the lesion and cures the patient.

Our probe is equipped with a proprietary temperature sensor, coupled with a predictive software, enabling real-time monitoring and control of the ablation zone for safer, more efficient, and reproducible treatments.

Lung cancer is the deadliest cancer with more than 2.1 million patients dying from lung cancer every year. The number of early-detected lung cancer patients is ramping up with the deployment of lung cancer screening programs worldwide, creating a large demand for early-stage lung cancer patients management and a need for minimally-invasive treatment to replace surgery.

Hepta Medical targets a current 2.5B€ market worldwide, expected to grow to 7B€ within the next years.